|
# # # # The outcome of a major Phase 2 clinical trial testing the safety and efficacy of a new class of drug – a LRRK2 inhibitor – has just been announced and the agent was found to have no impact on slowing the progression of symptoms in people with early idiopathic Parkinson’s. The drug in question is called “BIIB122” and it has been developed by Denali Therapeutics (in partnership with the pharma company Biogen). While the news is disappointing, we need to wait and see the full results before drawing too many conclusions. In addition, the key word in the sentences above may be “idiopathic”. The real test for this class of agent is probably still to come. In today’s post, we will discuss the press release, review what a LRRK2 inhibitor is, and consider what this means for our theories of the underlying biology driving Parkinson’s. # # # # |
Source: Scientificamerican
When I boarded a plane in London, heading for Phoenix to attend the 2026 World Parkinson’s Congress, all was well in the world.
As I settled in my seat, I checked the news on my phone and found that everything was normal (or at least as normal as it can be in the orange fruit cake world).
When the plane touched down in Phoenix, however, the news was suddenly alive with an announcement from the biotech companies Biogen and Denali Therapeutics.
What did they report?
They said that their LUMA clinical trial had not met its primary endpoint.
What is the LUMA study? And what is a “primary endpoint”?
The Science of Parkinson's 